In cancer cells with high levels of p‐TFCP2L1, CDK1, SALL4, and CD44 levels were significantly higher than in cells with low expression of p‐TFCP2L1 (Fig 4D), suggesting that a subset of p‐TFCP2L1‐positive cells could represent a population of bladder CSCs. This evidence concerns the gene TFCP2L1 and cancer.